Aqualis Report issue

For profit Phase 2 Phase 3
Founded: Oslo Norway (2001)
Status: Left NME R&D (2017)

Organization Overview

First Clinical Trial
2005
NCT00232726
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

cytarabine (cytosar-u) (1 trial)

elacytarabine (9 trials)

Drugs in Phase 2 Trials (2)

gemcitabine (gemzar) (2 trials)

sorafenib (nexavar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Colorectal Neoplasms (Phase 2)

Leukemia (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Melanoma (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 4